
Catalent Investor Relations Material
Latest events

Investor Update
Catalent

Q1 2025
5 Nov, 2024

Q4 2024
29 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Catalent Inc
Access all reports
Catalent, Inc. is a global contract development and manufacturing organization and provider of research, analytical and clinical services. Catalent offers integrated discovery, development and manufacturing solutions including late stage clinical, sterile process design, commercial production and development solutions for biologics and over-the-counter health drug products.
The company also provides comprehensive pharmaceutical services through established early phase development capabilities in small molecule API drug development and late phase clinical development capabilities in global multi-site clinical trials. In addition to biopharmaceuticals and OTC services, Catalent provides an integrated suite of R&D services, including protein chemistry and analytical testing to support non-biotechnology clients developing diagnostics for use in the clinical laboratory. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
CTLT
Country
🇺🇸 United States